First Innovator of the Year from Venture Industry

Waltham, MA – August 21, 2007 – Adnexus Therapeutics, Inc. today announced Timothy J. Rink, MD, ScD has joined the Adnexus Board of Directors. Dr. Rink also currently serves as chairman of the Strategy Panel of the Technology Transfer division of the Wellcome Trust that funds biomedical research, and serves on the boards of Santhera Pharmaceuticals (SWX: SANN) and Sepracor, Inc. (NASDAQ: SEPR) and the scientific advisory board of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).

Waltham, MA – August 21, 2007 – Adnexus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares in the offering will be sold by Adnexus.

The book-running managers of the proposed offering will be Lehman Brothers and UBS Securities LLC, and Cowen and Company and Lazard Freres & Co LLC will serve as co-managers.

AMSTERDAM, The Netherlands and BURLINGTON, Mass., Aug. 27 /PRNewswire/ -- Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced it has completed its acquisition of Color Kinetics Incorporated, a leader in designing and marketing innovative lighting systems based on Light Emitting Diode (LED) technology. As a result of the transaction, Color Kinetics will be financially consolidated with immediate effect within the Luminaires business group of Philips' Lighting division.

Cambridge, MA (September 4, 2007) — Ensemble Discovery Corporation, a biotechnology company developing novel classes of therapeutics and bioassays using its proprietary DNA Programmed Chemistry™ (DPC™) platform, today announced that it has appointed Michael D. Taylor, Ph.D. as President and Chief Executive Officer and to the company’s Board of Directors.

WALTHAM, MA - September 12, 2007 -- Epitome Biosystems, a leader in quantitative protein measurement solutions, announced today the appointment of Edward Machuga to Vice President, Sales and Marketing. In this newly created position, Mr. Machuga will be responsible for all commercial activities, including sales of the newly launched Ti-Tyr™ Profiling Chip and Q-SONAR™ Discovery Service, as well as other products that will emerge from Epitome’s pipeline. Mr.

Bristol-Myers Squibb to advance biologics strategy through targeted biologics acquisition

October 2, 2007, Sydney, Australia and Cambridge, MA – Peptech Limited (ASX: PTD) and AVEO Pharmaceuticals Inc. today announced they have entered into a non-exclusive research and commercialisation agreement in which AVEO will access Peptech’s SuperhumanisationTM technology to humanise internally-derived drug candidates.

OSI to Host Conference Call / Webcast

Stan Lapidus Appointed Chairman of the Board of Directors